Omicron Infection Enhances Delta Antibody Immunity in Vaccinated Persons

The extent to which Omicron infection, with or without previous vaccination, elicits protection against the previously dominant Delta (B.1.617.2) variant is unclear. Here we measured the neutralization capacity against variants of severe acute respiratory syndrome coronavirus 2 in 39 individuals in South Africa infected with the Omicron sublineage BA.1 starting at a median of 6 (interquartile range 3-9) days post symptom onset and continuing until last follow-up sample available, a median of 23 (interquartile range 19-27) days post symptoms to allow BA.1-elicited neutralizing immunity time to develop. Fifteen participants were vaccinated with Pfizer's BNT162b2 or Johnson & Johnson's Ad26.CoV2.S and had BA.1 breakthrough infections, and 24 were unvaccinated. BA.1 neutralization increased from a geometric mean 50% focus reduction neutralization test titre of 42 at enrolment to 575 at the last follow-up time point (13.6-fold) in vaccinated participants and from 46 to 272 (6.0-fold) in unvaccinated participants. Delta virus neutralization also increased, from 192 to 1,091 (5.7-fold) in vaccinated participants and from 28 to 91 (3.0-fold) in unvaccinated participants. At the last time point, unvaccinated individuals infected with BA.1 had low absolute levels of neutralization for the non-BA.1 viruses and 2.2-fold lower BA.1 neutralization, 12.0-fold lower Delta neutralization, 9.6-fold lower Beta variant neutralization, 17.9-fold lower ancestral virus neutralization and 4.8-fold lower Omicron sublineage BA.2 neutralization relative to vaccinated individuals infected with BA.1. These results indicate that hybrid immunity formed by vaccination and Omicron BA.1 infection should be protective against Delta and other variants. By contrast, infection with Omicron BA.1 alone offers limited cross-protection despite moderate enhancement.

Citing Articles

The consequences of SARS-CoV-2 within-host persistence.

Sigal A, Neher R, Lessells R Nat Rev Microbiol. 2024; .

PMID: 39587352 DOI: 10.1038/s41579-024-01125-y.

Maternal Preconception COVID-19 Vaccination and Its Protective Effect on Infants after a Breakthrough Infection during Pregnancy.

Yang Y, Hu J, Deng H, Chen D, Wu G, Xing H Vaccines (Basel). 2024; 12(10).

PMID: 39460299 PMC: 11511423. DOI: 10.3390/vaccines12101132.

Vaccination against rapidly evolving pathogens and the entanglements of memory.

Cobey S Nat Immunol. 2024; 25(11):2015-2023.

PMID: 39384979 DOI: 10.1038/s41590-024-01970-2.

Durability of immune responses to SARS-CoV-2 infection and vaccination.

Suthar M Semin Immunol. 2024; 73:101884.

PMID: 38861769 PMC: 11490408. DOI: 10.1016/j.smim.2024.101884.

SARS-CoV-2 Neutralizing Antibodies in Three African Countries Following Multiple Distinct Immune Challenges.

Ny Mioramalala D, Ratovoson R, Tagnouokam-Ngoupo P, Abessolo H, Mindimi Nkodo J, Mayaka G Vaccines (Basel). 2024; 12(4).

PMID: 38675745 PMC: 11054809. DOI: 10.3390/vaccines12040363.

References

Goldberg Y, Mandel M, Bar-On Y, Bodenheimer O, Freedman L, Haas E . Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021; 385(24):e85. PMC: 8609604. DOI: 10.1056/NEJMoa2114228. View

Davies M, Kassanjee R, Rousseau P, Morden E, Johnson L, Solomon W . Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. Trop Med Int Health. 2022; 27(6):564-573. PMC: 9115442. DOI: 10.1111/tmi.13752. View

Khan K, Lustig G, Bernstein M, Archary D, Cele S, Karim F . Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2021; 75(1):e857-e864. PMC: 8689810. DOI: 10.1093/cid/ciab1008. View

Cele S, Gazy I, Jackson L, Hwa S, Tegally H, Lustig G . Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021; 593(7857):142-146. PMC: 9867906. DOI: 10.1038/s41586-021-03471-w. View

Cele S, Karim F, Lustig G, San J, Hermanus T, Tegally H . SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe. 2022; 30(2):154-162.e5. PMC: 8758318. DOI: 10.1016/j.chom.2022.01.005. View

Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E . Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532-1546. PMC: 8908811. DOI: 10.1056/NEJMoa2119451. View

Sigal A . Milder disease with Omicron: is it the virus or the pre-existing immunity?. Nat Rev Immunol. 2022; 22(2):69-71. PMC: 8767774. DOI: 10.1038/s41577-022-00678-4. View

Dejnirattisai W, Shaw R, Supasa P, Liu C, Stuart A, Pollard A . Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet. 2021; 399(10321):234-236. PMC: 8687667. DOI: 10.1016/S0140-6736(21)02844-0. View

Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M . Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022; 399(10323):437-446. PMC: 8769664. DOI: 10.1016/S0140-6736(22)00017-4. View

10.

Sigal A, Milo R, Jassat W . Estimating disease severity of Omicron and Delta SARS-CoV-2 infections. Nat Rev Immunol. 2022; 22(5):267-269. PMC: 9002222. DOI: 10.1038/s41577-022-00720-5. View

11.

Cao Y, Jian F, Xiao T, Song W, Yisimayi A, Huang W . Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022; 602(7898):657-663. PMC: 8866119. DOI: 10.1038/s41586-021-04385-3. View

12.

Richardson S, Madzorera V, Spencer H, Manamela N, van der Mescht M, Lambson B . SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe. 2022; 30(6):880-886.e4. PMC: 8947963. DOI: 10.1016/j.chom.2022.03.029. View

13.

Madhi S, Kwatra G, Myers J, Jassat W, Dhar N, Mukendi C . Population Immunity and Covid-19 Severity with Omicron Variant in South Africa. N Engl J Med. 2022; 386(14):1314-1326. PMC: 8908853. DOI: 10.1056/NEJMoa2119658. View

14.

Viana R, Moyo S, Amoako D, Tegally H, Scheepers C, Althaus C . Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022; 603(7902):679-686. PMC: 8942855. DOI: 10.1038/s41586-022-04411-y. View

15.

Dejnirattisai W, Huo J, Zhou D, Zahradnik J, Supasa P, Liu C . SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022; 185(3):467-484.e15. PMC: 8723827. DOI: 10.1016/j.cell.2021.12.046. View

16.

Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J . Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022; 602(7898):671-675. DOI: 10.1038/s41586-021-04389-z. View

17.

Cele S, Jackson L, Khoury D, Khan K, Moyo-Gwete T, Tegally H . Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022; 602(7898):654-656. PMC: 8866126. DOI: 10.1038/s41586-021-04387-1. View

18.

Rossler A, Riepler L, Bante D, von Laer D, Kimpel J . SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. N Engl J Med. 2022; 386(7):698-700. PMC: 8781314. DOI: 10.1056/NEJMc2119236. View

19.

Chemaitelly H, Ayoub H, Coyle P, Tang P, Yassine H, Al-Khatib H . Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. Nat Commun. 2022; 13(1):4675. PMC: 9362989. DOI: 10.1038/s41467-022-32363-4. View

20.

Khoury D, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8. View